CAR-T-derived extracellular vesicles: a promising development of CAR-T anti-tumor therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Cancers (2023) 15:4, 1052. https://doi.org/10.3390/cancers15041052
- Ereignis
-
Veröffentlichung
- (wo)
-
Würzburg
- (wer)
-
Universität Würzburg
- (wann)
-
2023
- Urheber
-
Pagotto, Sara
Simeone, Pasquale
Brocco, Davide
Catitti, Giulia
De Bellis, Domenico
Vespa, Simone
Di Pietro, Natalia
Marinelli, Lisa
Di Stefano, Antonio
Veschi, Serena
De Lellis, Laura
Verginelli, Fabio
Kaitsas, Francesco
Iezzi, Manuela
Pandolfi, Assunta
Visone, Rosa
Tinari, Nicola
Caruana, Ignazio
Di Ianni, Mauro
Cama, Alessandro
Lanuti, Paola
Florio, Rosalba
- DOI
-
10.3390/cancers15041052
- URN
-
urn:nbn:de:bvb:20-opus-304195
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pagotto, Sara
- Simeone, Pasquale
- Brocco, Davide
- Catitti, Giulia
- De Bellis, Domenico
- Vespa, Simone
- Di Pietro, Natalia
- Marinelli, Lisa
- Di Stefano, Antonio
- Veschi, Serena
- De Lellis, Laura
- Verginelli, Fabio
- Kaitsas, Francesco
- Iezzi, Manuela
- Pandolfi, Assunta
- Visone, Rosa
- Tinari, Nicola
- Caruana, Ignazio
- Di Ianni, Mauro
- Cama, Alessandro
- Lanuti, Paola
- Florio, Rosalba
- Universität Würzburg
Entstanden
- 2023
Ähnliche Objekte (12)
Engineering CAR-T cells
FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer
Preclinical development of CD126 CAR-T cells with broad antitumor activity
Superior anti-tumor efficacy of CD4⁺ CAR-T cells in hematological malignancies
Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies
Strategies to enhance CAR-T persistence
Gut microbiome and CAR-T therapy
Target selection for CAR-T therapy
Interleukin-7 expression by CAR-T cells improves CAR-T cell survival and efficacy in chordoma
Engineering CAR-T cells
FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer
Preclinical development of CD126 CAR-T cells with broad antitumor activity
Superior anti-tumor efficacy of CD4⁺ CAR-T cells in hematological malignancies
Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies
Strategies to enhance CAR-T persistence
Gut microbiome and CAR-T therapy
Target selection for CAR-T therapy
Interleukin-7 expression by CAR-T cells improves CAR-T cell survival and efficacy in chordoma
Engineering CAR-T cells
FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer
Preclinical development of CD126 CAR-T cells with broad antitumor activity
Superior anti-tumor efficacy of CD4⁺ CAR-T cells in hematological malignancies
Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies
Strategies to enhance CAR-T persistence
Gut microbiome and CAR-T therapy
Target selection for CAR-T therapy